GHK-Cu Subcutaneous vs. Topical: Maximising Systemic Collagen Synthesis

What GHK-Cu Does

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the most studied copper peptides in biology. It is found naturally in human plasma at concentrations that decline with age — from approximately 200ng/ml at age 20 to 80ng/ml by age 60.

Its biological activities operate primarily through copper-dependent enzyme activation: GHK-Cu delivers copper ions to enzymes that require copper as a cofactor — particularly lysyl oxidase (crosslinks collagen and elastin), superoxide dismutase (antioxidant), and ceruloplasmin (iron metabolism).

Beyond simple copper delivery, GHK itself has receptor-mediated effects: it activates integrins on fibroblasts, stimulating collagen type I and III synthesis directly, and upregulates TGF-β — a key growth factor for connective tissue repair. ^[]

The Human Evidence for Topical Application

Topical GHK-Cu has the most robust human evidence in any peptide category outside of pharmaceuticals. Multiple controlled trials in cosmetic dermatology have shown: ^[]

• Increased skin thickness (direct measure of dermal collagen density)
• Reduced fine lines and wrinkles
• Improved skin elasticity
• Faster wound closure and improved scar quality
• Reduced post-procedure inflammation

A 2008 clinical study directly comparing GHK-Cu cream versus vehicle control showed significant improvements in skin texture, tightness, and reduction of fine lines at 12 weeks in women aged 40–60.

This evidence base makes topical GHK-Cu one of the most evidence-supported skincare active ingredients available — well beyond the typical cosmetic claim evidence standard.

When to Choose Subcutaneous

Topical application reaches skin dermis effectively but cannot reach deep connective tissue — tendons, ligaments, cartilage, and bone — where systemic GHK-Cu is needed.

Indications for subcutaneous GHK-Cu:

• Tendon and ligament repair protocols (typically combined with TB-500 and BPC-157)
• Cartilage support (osteoarthritis, post-injury)
• Systemic connective tissue remodelling
• Bone density support (GHK-Cu promotes bone matrix protein synthesis)

Subcutaneous injection distributes GHK-Cu via the bloodstream to all connective tissues — the copper peptide acts as a systemic collagen synthesis signal.

Dosing Protocol

Topical:

• Concentration: 1–2% GHK-Cu in an appropriate base (serum, cream, or liposomal)
• Application: Morning and evening on cleansed skin
• Target areas: Face, neck, décolletage for anti-ageing; wound/scar sites for healing support
• Daily use is appropriate — no cycling needed for topical

Subcutaneous:

• Dose: 1–2mg/day
• Injection: Subcutaneous, rotating sites
• Cycle: 8–12 weeks on, 4 weeks off
• Combine with TB-500 (systemic healing support) for connective tissue protocols

The Copper Toxicity Consideration

GHK-Cu is a copper delivery system — this creates a genuine upper limit. The tolerable upper intake level (UL) for copper is 10mg/day from all sources. Research peptide GHK-Cu doses (1–2mg/day) are well below this limit, but the total dietary copper exposure should be considered.

Signs of copper excess: nausea, vomiting, abdominal cramping. Copper and zinc compete for absorption — high copper supplementation can create zinc deficiency over time. Do not combine GHK-Cu with other copper supplementation.

The Anti-Cancer Data

One of GHK's more striking research findings: it modulates gene expression in a manner that reverses the gene signature of metastatic colon cancer cells toward a non-metastatic phenotype — downregulating 59% of overexpressed genes in the metastatic line.

This is in vitro cell culture data only — not clinical evidence for cancer prevention. But the mechanistic finding is striking and has driven interest in GHK-Cu as a potential anti-ageing compound beyond its collagen effects. Human clinical data for oncological applications does not currently exist.